Thank you, Mr. Chairman.
Dr. Gulenchyn, in speaking about alternative diagnostic tests to those using moly-based medical isotopes, you mentioned that restrictions to use increase with cost and availability. To what extent are patients being told that cancer treatment cannot be conducted because of the possible costs related to using other diagnostic methods?